文献速递前列腺癌

高危局限性前列腺癌新辅助强化激素治疗联合手术的结局:当代临床试验汇总分析

Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials.
PubMed 文献 · J Urol · 2021-01-27

该汇总分析纳入3项随机多中心临床试验中接受强化新辅助雄激素剥夺治疗(ADT)后行根治性前列腺切除术的患者,评估术后生化复发等结局。结果显示,病理反应优异(残留肿瘤0-5 mm)者生化复发率低,PTEN缺失和导管内癌与更短生化复发时间相关。

要点

  • 新辅助强化ADT后病理反应优异与生化复发改善相关。
  • PTEN缺失和导管内癌与更短生化复发时间相关。
  • 需进一步随访评估长期结局。

核心结论

  • 新辅助强化ADT后病理反应优异对生化复发有有利影响。
  • PTEN缺失和导管内癌与生化复发相关。

研究设计与样本

  • 汇总分析3项随机多中心临床试验,评估强化新辅助ADT后根治性前列腺切除术的结局。
  • 共纳入117例患者,其中78.6%(92例)为高危疾病。
  • 主要终点为生化复发时间,定义为根治性前列腺切除术后PSA>0.1 ng/ml或开始首次术后治疗的时间,按病理反应分层。

主要发现

  • 21.4%(25例)有0-5 mm残留肿瘤,包括9.4%(11例)病理完全缓解。
  • 49例(41.9%)发生生化复发,3年无生化复发率为59.1%(95% CI 49.0-67.9)。
  • 病理反应优异的25例中2例(8.0%)发生生化复发,而无反应者中51.1%(47/92)发生生化复发。
  • 93.8%(106/113)患者观察到睾酮恢复。

临床怎么用

  • 新辅助强化ADT后病理反应优异可提示较好的生化复发结局。
  • PTEN缺失和导管内癌可能有助于识别生化复发风险较高的患者。

局限性

  • 需进一步随访评估对长期结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report on the post-radical prostatectomy outcomes of patients enrolled in 3 randomized, multicenter, clinical trials of intense neoadjuvant androgen deprivation therapy prior radical prostatectomy. MATERIALS AND METHODS: All patients included were enrolled in trials evaluating intense androgen deprivation therapy followed by radical prostatectomy. The primary end point was time to biochemical recurrence, defined as the time from radical prostatectomy to prostate specific antigen >0.1 ng/ml or start of first post-radical prostatectomy therapy, stratified by pathological response at radical prostatectomy (presence or absence of exceptional pathological response defined as residual tumor at radical prostatectomy measuring 0-5 mm). Secondary end points included metastasis-free survival, overall survival, and time to testosterone recovery. RESULTS: Overall, 117 patients were included in the analysis, of whom 78.6% (92) had high risk disease. Following neoadjuvant therapy, 21.4% (25) had 0-5 mm of residual tumor, including 9.4% (11) with a pathological complete response. Overall, 49 patients (41.9%) experienced biochemical recurrence and the 3-year biochemical recurrence-free rate was 59.1% (95% CI 49.0-67.9). Of the 25 patients with an exceptional pathological response, 2 patients (8.0%) developed biochemical recurrence while 51.1% of nonresponders (47/92) developed biochemical recurrence. Testosterone recovery was observed in 93.8% of patients (106/113). PTEN loss and intraductal carcinoma were associated with shorter time to biochemical recurrence. CONCLUSIONS: In this pooled analysis of prospective trials, we demonstrate that exceptional pathological response following neoadjuvant therapy is associated with a favorable impact on biochemical recurrence. PTEN loss and intraductal carcinoma were associated with biochemical recurrence. Additional followup is warranted to evaluate the impact on long-term outcomes.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. McKay RR, Berchuck J, Kwak L, et al. Outcomes of Post-Neoadjuvant Intense Hormone Therapy and Surgery for High Risk Localized Prostate Cancer: Results of a Pooled Analysis of Contemporary Clinical Trials. J Urol. 2021. PMID: 33502237. doi:10.1097/JU.0000000000001632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。